SIRPA and neoplasm: Moreover, combining extracellular BAG3 blockade with immune checkpoint inhibitors (such as anti-SIRP-α or anti-PD-1 antibodies) (46, 47) yields synergistic enhancement of anti-tumor immune responses beyond immune checkpoint inhibition alone.